---
title: "LiBang Pharma-B falls 5% in Hong Kong trading"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292135100.md"
description: "LiBang Pharma-B (9637.HK) dropped 5.59% to HK$31.520 during regular trading with no obvious catalyst."
datetime: "2026-07-09T02:00:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292135100.md)
  - [en](https://longbridge.com/en/news/292135100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292135100.md)
generator: "portal-rs"
---

# LiBang Pharma-B falls 5% in Hong Kong trading

LiBang Pharma-B (9637.HK) **fell** **5.59%** **during regular trading** to **HK$31.520**.

No clear catalyst was identified.

### Related Stocks

- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)

## Related News & Research

- [Alebund Pharmaceuticals schedules board meeting to review interim results](https://longbridge.com/en/news/295791812.md)
- [Alebund Pharma says China NMPA accepts AP301 hyperphosphatemia NDA for review](https://longbridge.com/en/news/295210484.md)
- [Marshall Wace discloses net short position in Capital B shares](https://longbridge.com/en/news/296625312.md)
- [Kuaishou files HKEX next-day disclosure return, share capital rises by 213,553 shares](https://longbridge.com/en/news/296482134.md)
- [Shanghai Bao Pharma says FDA clears IND for KJ015 anti-HER2 bispecific antibody injection](https://longbridge.com/en/news/296768130.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**